论文部分内容阅读
2014年3月,国内抗感染领域多个学科的临床专家与四川大学华西医院中国循证医学中心的方法学专家在成都启动了国内外感染性疾病指南的解读工作。这项工作旨在重新审视和评价我国临床实践与以欧美为主的各相关学科感染性疾病诊治指南的关系。感染性疾病的治疗面临世界性难题,其焦点就是病菌耐药性增长迅速,而新的有效药物研发远远落后,甚至有来自英国的一项研究预测,到2050年中国每年将有100万患者死于多重耐药细菌感染。面对这一严重局面,研制全新机制抗感染药自然重要,但因其难度增大,耗资过高,耗时过长,令许多
In March 2014, clinical experts from multiple disciplines in the field of anti-infectives in China and methodologists from the China Evidence-Based Medical Center at West China Hospital of Sichuan University started the interpretation of guidelines on infectious diseases at home and abroad in Chengdu. The purpose of this work is to re-examine and evaluate the relationship between clinical practice in our country and guidelines for the diagnosis and treatment of infectious diseases in all relevant disciplines that are predominantly in Europe and the United States. The treatment of infectious diseases faces worldwide challenges, the focus of which is the rapid increase in drug-resistant germs, while the development of new and effective drugs lags far behind. There is even a study from the UK that predicts that by 2050, China will have 1 million patients annually Died of multiple drug-resistant bacterial infections. In the face of this serious situation, it is naturally important to develop a new anti-infective drug mechanism. However, due to its increased difficulty, excessive cost and time-consuming activities, many